BioCentury
ARTICLE | Clinical News

Lesinurad meets in Phase III gout trial

December 14, 2013 1:29 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said once-daily lesinurad ( RDEA594) met the primary endpoint of a greater proportion of patients achieving serum uric acid (sUA) levels of less than 6 mg/dL at six months vs. placebo (p<0.0001) in the Phase III LIGHT trial to treat gout. The double-blind, international trial enrolled 214 gout patients with baseline sUA levels of 6.5 mg/dL or greater who are intolerant or have a contraindication to allopurinol or febuxostat. The pharma expects data in mid-2014 from the Phase III CLEAR1 and CLEAR2 trials, which are also evaluating the compound for gout. ...